ISRCTN13241761进行中（未招募）Unknown
Intestinal Microbiota Transplant Prior to Allogeneic Stem Cell Transplant (MAST) trial
适应症
试验速览
- 阶段
- Unknown
- 状态
- 进行中（未招募）
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Patients aged 18 years and over with a morphological documented diagnosis of ALL, AML, AL of ambiguous linage, MDS, CMML, and CML in blast phase who are deemed fit for allogenic HSCT with one of the following disease characteristics:
- •ALL, AML, AL of ambiguous linage
- •1.1. Patients in first complete remission (CR1) or second complete remission (CR2) including complete remission with incomplete blood count recovery with < 5% blasts
- •1.2. Secondary leukaemia (defined as previous history of MDS, antecedent haematological disease or chemotherapy exposure) in CR1 or CR2 defined as < 5% blasts
- •MDS and CMML
- •1.3. Patients with advanced or high-risk MDS with an IPSS-M moderate high or higher including intermediate or high-risk CMML who have < 5% blasts at the time of randomisation
- •CML in the blast phase
- •1.4. Patients with Philadelphia or BCR:ABL1 positive chronic myeloid leukaemia (CML) in blast phase defined by the presence of = 20% blasts in the blood or bone marrow who have achieved second chronic phase with < 5% blasts (Appendix 2).
- •2. Patients must have completed a minimum of two cycles of intensive chemotherapy prior to trial enrolment (Appendix 1)
- •3. Patients must have received broad-spectrum antibiotics within 3 months prior to trial enrolment
- •4. Patients must be considered suitable/fit to undergo allogeneic HSCT as clinically judged by the Local investigator
- •5. Patients with a Karnofsky performance status score of 60 or above (Appendix 3)
- •6. Females and male patients of reproductive potential (i.e., not post-menopausal or surgically sterilised) must use appropriate, highly effective, contraception from the point of commencing therapy until 6 months after treatment
- •7. Patients have given written informed consent
- •8. Patients willing and able to comply with scheduled study visits and laboratory tests
排除标准
- •1. Patients with contraindications to receiving allogeneic HSCT
- •2. Female patients who are pregnant or breastfeeding. All women of childbearing potential must have a negative pregnancy test before commencing treatment
- •3. Adults of reproductive potential not willing to use appropriate, highly effective, contraception during the specified period
- •4. Patients with renal or hepatic impairment as clinically judged by the Local Investigator
- •5. Patients with active infection, HIV-positive or chronic active HBV or HCV.
- •6. Patients with a concurrent active malignancy or a prior malignancy, except lobular breast carcinoma in situ, fully resected basal cell or squamous cell carcinoma of the skin or treated cervical carcinoma in situ, an incidental histologic finding of prostate cancer (T1a or T1b using the tumour, node, metastasis (TNM) clinical staging system), previous MDS, CMML, MPN resulting in secondary AML. Cancer treated with curative intent = 5 years previously will be allowed. Cancer treated with curative intent < 5 years previously will not be allowed
- •7. Swallowing difficulties that may preclude the safe use of IMT capsules
- •8. Administration of IMT within 3 months prior to enrolment (probiotic administration prior to enrolment is allowed but should be recorded at screening).
- •9. Patients taking probiotics after enrolment in the trial
- •10. Chronic intestinal disease, including coeliac disease, cystic fibrosis, inflammatory bowel disease, irritable bowel syndrome, and chronic diarrhoea
- •11. Known severe allergy to capsule components
研究者
相似试验
招募中
2 期
A-FMT for active UCMild to moderate ulcerative colitisUlcerative colitisJPRN-jRCTs031220542agahara Akihito37
进行中（未招募）
Unknown
Role of transplantation of fecal microbiota from healthy individuals to patients with Crohn's disease and its effect on achieving control of disease activityCrohn's disease of both small and large intestineDigestive SystemISRCTN15318304Dayanand Medical College & Hospital36
招募中
2 期
Fecal microbiota transplantation for intractable gastrointestinal diseases(FEMIGI study)1)Clostridium difficile infection 2)Crohn disease, ulcerative colitis 3)Chronic Enteropathy associatJPRN-jRCTs041190021Ohmiya Naoki50
招募中
2 期
Intestinal Microbiota Transplant Prior to Allogeneic Stem Cell Transplant (MAST) TrialAcute Lymphoblastic LeukaemiaAcute Leukemia of Ambiguous LineageChronic Myeloid LeukemiaAcute Myeloid LeukemiaChronic Myelomonocytic LeukemiaMyelodysplastic SyndromeNCT06355583Imperial College London50
Unknown
1 期
Fecal Microbiota Transplantation for Steroid Resistant and Steroid Dependent Gut Acute Graft Versus Host DiseaseStem Cell Transplant ComplicationsGraft Versus Host Disease, AcuteFecal Microbiota TransplantationNCT03214289Sheba Medical Center4